# Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an IPAA (PROF)

> **NCT05938465** · PHASE1,PHASE2 · RECRUITING · sponsor: **Exegi Pharma, LLC** · enrollment: 50 (estimated)

## Conditions studied

- Ileal Pouch

## Interventions

- **BIOLOGICAL:** EXE-346
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05938465
- **Lead sponsor:** Exegi Pharma, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-06
- **Primary completion:** 2026-05
- **Final completion:** 2026-06
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05938465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05938465, "Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an IPAA (PROF)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05938465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*